查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993607

全球特发性肺纤维化市场：按治疗方法和地区划分－市场规模、产业趋势、机会分析和未来预测（2026-2035 年）

Global Idiopathic Pulmonary Fibrosis Market: By Therapy, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计未来十年，特发性肺纤维化 (IPF) 市场将显着成长，反映出市场对有效治疗方法的需求不断增长以及医疗技术的进步。到 2025 年，市场规模预计将达到约 29.7069 亿美元，到 2035 年，这一数字预计将翻一番以上，达到 67.3649 亿美元。这一显着成长意味着 2026 年至 2035 年的复合年增长率 (CAGR) 将达到 9.4%，凸显了市场成长的强劲势头。

目前，抗纤维化疗法主导着特发性肺纤维化（IPF）市场，其中Pirfenidone和尼达尼布是用于延缓IPF进展的核心药物。这些药物已证实能有效抑制肺功能下降，进而改善患者的预后和生活品质（QOL）。它们在各个地区的广泛应用凸显了其在临床实践中的关键作用。然而，随着研究日益聚焦于标靶治疗和新型治疗方法的开发，IPF市场正经历转型，这些疗法和疗法能够更精准地针对疾病的潜在机制。

显着的市场趋势

特发性肺纤维化（IPF）市场集中度较高，少数几家主要企业占了大部分市场。这些主要企业凭藉着全面的产品系列、丰富的临床经验和完善的分销网络，奠定了坚实的基础。然而，随着研发投入的增加和生技领域创新成果的涌现，这种集中格局正逐渐受到衝击。

主要企业包括勃林格殷格翰、罗氏、Astra Zeneca和百时美施贵宝等老牌製药巨头。这些公司利用其雄厚的资源和丰富的经验，推动治疗药物的研发，进行大规模临床试验，并获得监管部门的核准。除了这些全球领导者外，像Priant Therapeutics、Fibrogen和Vicore Pharma这样的小型生物技术公司也在不断扩大其市场份额，它们专注于创新作用机制，并针对IPF进展过程中涉及的特定通路。

目前，特发性肺纤维化（IPF）市场主要由两款产品支撑：基因泰克公司生产的Esbury（Pirfenidone）和勃林格殷格翰公司开发的Ofev（尼达尼布）。这两种药物都已被证实能有效延缓疾病进展并改善患者的生活质量，因此成为IPF的标准治疗方案。它们在各个地区的广泛应用凸显了其重要的临床价值和商业性成功。

主要成长要素

特发性肺纤维化 (IPF) 市场正经历快速扩张，主要驱动因素是人口结构变化，尤其是60岁及以上老年人口的增长。此年龄层尤其容易罹患IPF，约占确诊患者的三分之二。随着美国、欧盟和亚太地区等主要地区人口老化，预计IPF的盛行率也将随之上升。这一人口趋势显着提升了对有效治疗方法的需求，预计未来几年IPF市场将保持强劲增长，复合年增长率 (CAGR) 也将保持在较高水平。

新机会的趋势

将人工智慧（AI）引入高解析度电脑断层扫描（HRCT）影像的解读，显着提高了特发性肺纤维化（IPF）的诊断水平，有助于临床实践的标准化和准确性提升。传统上，使用HRCT诊断IPF需要识别复杂的肺部影像模式，例如蜂窝状改变，这些模式非常细微，放射科医生难以准确识别。人为解读的差异常导致诊断延迟或误诊，影响患者的预后和治疗的及时性。然而，人工智慧演算法的引入正在迅速改变这一现状，为放射科医生提供了一个强大的工具，以增强其检测能力并提高诊断信心。

优化障碍

高昂的治疗费用是阻碍市场成长的一大挑战。昂贵的治疗方法往往会造成就医障碍，尤其对于没有全面医疗保险或居住在医疗预算有限地区的患者而言更是如此。当治疗费用过高时，许多患者可能会推迟或放弃必要的治疗。这不仅会影响个人的健康状况，还会抑制整体市场需求。对于需要长期服药的慢性病和复杂疾病，这种经济负担尤其沉重，因为随着时间的推移，累积费用会显着增加。

按细分市场划分

透过治疗方法

  • 埃斯伯里（Pirfenidone）
  • Ofev（尼达尼布）
  • 蒂珀卡斯特
  • 帕姆列乌鲁单抗
  • KD025
  • PRM 151
  • GKT831
  • 其他的

国家

  • 我们
  • 英国
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 日本

按地区划分

  • 北美仍然是特发性肺纤维化 (IPF) 市场的绝对领导者，其中美国发挥主导作用。这种主导地位源自于多种因素，包括高诊断率（反映出完善的医疗基础设施）和对疾病的广泛认知。此外，该地区受益于成熟的保险报销体系，使患者能够便捷地获得高品质的抗纤维化疗法，这些疗法对于控制和延缓 IPF 的进展至关重要。
  • 美国国立卫生研究院 (NIH) 于 2025 年进行的一项综合Meta分析凸显了特发性肺纤维化 (IPF) 在北美地区极高的盛行率，估计约为每 10 万人中有 27.2 例。这一患病率显着高于其他大洲，印证了该地区独特的流行病学特征。较高的诊断率（可能得益于更完善的筛检和报告系统）导致患者数量不断增加，从而为专注于 IPF 治疗的製药公司带来了更大的商机。

主要市场参与企业

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH, and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • Biogen, Inc.
  • Merck and Co.
  • Novartis
  • 其他主要企业

目录

第一章：分析框架

  • 分析目的
  • 产品概述
  • 市场区隔

第二章 分析方法

  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 主要调查受访者组成：按地区划分
  • 本报告的前提条件
  • 市场规模估算
  • 数据检验

第三章执行摘要：全球特发性肺纤维化（IPF）市场

第四章 全球特发性肺纤维化（IPF）市场概述

  • 特发性肺纤维化概述
  • 产业价值链分析
    • 配方
    • 加工/包装
    • 销售代理
    • 最终用户
  • 产业展望
    • 流行病学和患者人群
    • 目前治疗方法
    • 未满足的需求
    • 为IPF做出贡献的组织
    • 关键意见领袖的观点：特发性肺纤维化
    • 病例报告
    • 非处方药
    • 正在研发中的药物

（**未完待续，请见最终报告**）

  • PESTLE分析
  • 波特五力分析
    • 供应商议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 任务
    • 主要趋势
  • 评估 COVID-19（冠状病毒）对市场成长趋势的影响
  • 市场成长及前景
    • 市场收益估算与预测（2017-2035）
    • 价格趋势分析
  • 竞争格局概述
    • 市场集中度
    • 企业市场占有率分析（以金额为准，2020 年）
    • 竞技地图

第五章：特发性肺纤维化市场分析：依治疗方法

  • 关键见解
  • 市场规模及预测（2017-2030 年）
    • 埃斯伯里（Pirfenidone）
    • Ofev（尼达尼布）
    • 蒂珀卡斯特
    • 帕姆列乌鲁单抗
    • KD025
    • PRM 151
    • GKT831
    • 其他的

第六章：特发性肺纤维化市场分析：按地区和国家划分

  • 关键见解
  • 市场规模及预测（2017-2030 年）
    • 我们
    • 英国
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 日本

第七章：美国特发性肺纤维化市场分析

第八章：英国特发性肺纤维化市场分析

第九章：法国特发性肺纤维化市场分析

第十章：德国特发性肺纤维化市场分析

第十一章：义大利特发性肺纤维化市场分析

第十二章：西班牙特发性肺纤维化市场分析

第十三章：日本特发性肺纤维化市场分析

第十四章：公司简介

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • BioGen, Inc.
  • Merck and Co.
  • Novartis
  • 其他主要企业
简介目录
Product Code: AA0721084

The Idiopathic Pulmonary Fibrosis (IPF) market is poised for significant growth over the next decade, reflecting a rising demand for effective treatments and advancements in medical technology. In 2025, the market is projected to generate approximately US$ 2,970.69 million, with estimates indicating that this figure will more than double to reach US$ 6,736.49 million by 2035. This substantial expansion corresponds to a compound annual growth rate (CAGR) of 9.4% during the period from 2026 to 2035, highlighting the strong momentum behind market growth.

The market is currently dominated by antifibrotic therapies, with Pirfenidone and Nintedanib being the cornerstone medications prescribed to slow the progression of IPF. These drugs have demonstrated clinical efficacy in reducing lung function decline, thereby improving patient outcomes and quality of life. Their widespread adoption across various regions underscores their vital role in the treatment landscape. However, the IPF market is undergoing a shift as research increasingly focuses on the development of targeted and novel therapies aimed at addressing the underlying mechanisms of the disease more precisely.

Noteworthy Market Developments

The idiopathic pulmonary fibrosis (IPF) market is characterized by a moderate to high level of concentration, with a relatively small number of key players controlling a significant share of the market. These leading companies have established strong footholds through robust product portfolios, extensive clinical expertise, and well-developed distribution networks. However, this concentration is gradually being challenged by increasing research and development efforts and a surge of innovation emerging from the biotechnology sector.

Among the major companies dominating the IPF market are well-established pharmaceutical giants such as Boehringer Ingelheim, Roche, AstraZeneca, and Bristol Myers Squibb. These firms have leveraged their extensive resources and experience to advance therapeutic development, conduct large-scale clinical trials, and secure regulatory approvals. In addition to these global leaders, smaller biotech companies like Pliant Therapeutics, FibroGen, and Vicore Pharma are gaining traction by focusing on innovative mechanisms of action and targeting specific pathways involved in the progression of IPF.

Currently, the market's therapeutic landscape is anchored by two primary products: Esbriet (Pirfenidone), marketed by Genentech, Inc., and Ofev (Nintedanib), developed by Boehringer Ingelheim Pharma GmbH & Co. KG. Both drugs have become standard-of-care treatments for IPF due to their proven efficacy in slowing disease progression and improving patients' quality of life. Their widespread adoption across various regions underscores their clinical importance and commercial success.

Core Growth Drivers

The Idiopathic Pulmonary Fibrosis (IPF) market is experiencing rapid expansion, largely driven by demographic shifts, particularly the increasing size of the geriatric population aged 60 and above. This age group is especially vulnerable to IPF, with approximately two-thirds of diagnosed patients falling into this category. As populations in key regions such as the United States, the European Union, and the Asia-Pacific continue to age, the prevalence of IPF is expected to rise correspondingly. This demographic trend significantly fuels demand for effective therapies, positioning the IPF market for robust growth characterized by a high compound annual growth rate (CAGR) over the coming years.

Emerging Opportunity Trends

The integration of Artificial Intelligence (AI) into the interpretation of High-Resolution Computed Tomography (HRCT) scans has brought about a significant advancement in the diagnosis of idiopathic pulmonary fibrosis (IPF), contributing to greater standardization and accuracy in clinical practice. Traditionally, diagnosing IPF through HRCT involves identifying complex lung patterns, such as honeycombing, which can be subtle and challenging for radiologists to detect consistently. Variability in human interpretation has often led to delays or misdiagnoses, affecting patient outcomes and treatment timeliness. However, the incorporation of AI algorithms into the diagnostic process is rapidly transforming this landscape by providing radiologists with powerful tools to enhance detection and improve diagnostic confidence.

Barriers to Optimization

The high cost of treatment poses a significant challenge that could potentially hamper the growth of the market. Expensive therapies often create barriers to access, especially for patients who lack comprehensive insurance coverage or live in regions with limited healthcare funding. When treatment costs are prohibitive, many patients may delay or forgo necessary care, which not only affects individual health outcomes but also constrains the overall market demand. This financial burden can be particularly acute for chronic or complex conditions requiring long-term medication, where cumulative expenses add up substantially over time.

Segment Breakdown

By Therapy

  • Esbriet (Pirfenidone)
  • Ofev (Nintedanib)
  • Tipelukast
  • Pamrevlumab
  • KD025
  • PRM 151
  • GKT831
  • Others

By Country

  • The U.S.
  • The UK
  • France
  • Germany
  • Spain
  • Italy
  • Japan

Geography Breakdown

  • North America continues to hold its position as the undisputed leader in the idiopathic pulmonary fibrosis (IPF) market, with the United States serving as the primary driving force behind this dominance. This leadership stems from multiple factors, notably a high diagnosis rate that reflects advanced healthcare infrastructure and widespread awareness of the disease. Additionally, the region benefits from a well-established reimbursement environment, which facilitates patient access to premium antifibrotic therapies that are essential for managing and slowing the progression of IPF.
  • A comprehensive meta-analysis conducted by the National Institutes of Health (NIH) in 2025 highlights the significant regional prevalence of IPF in North America, estimating approximately 27.2 cases per 100,000 individuals. This prevalence rate markedly exceeds that found in other continents, underscoring the unique epidemiological characteristics of the region. The higher diagnosis rates, likely due to superior screening and reporting mechanisms, contribute to a larger patient pool and, consequently, a greater commercial opportunity for pharmaceutical companies specializing in IPF therapies.

Leading Market Participants

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH, and Co. Kg
  • MediciNova
  • FibroGen, Inc.
  • Kadmon Corporation, LLC
  • Promedior
  • Genkyotex
  • CelgeneCorporation
  • ProMetic LifeSciences
  • Biogen, Inc.
  • Merck and Co.
  • Novartis
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Idiopathic Pulmonary Fibrosis (IPF) Market

Chapter 4. Global Idiopathic Pulmonary Fibrosis Market Overview

  • 4.1. Idiopathic Pulmonary Fibrosis Overview
  • 4.2. Industry Value Chain Analysis
    • 4.2.1. Formulation
    • 4.2.2. Processing & Packaging
    • 4.2.3. Distributor
    • 4.2.4. End users
  • 4.3. Industry Outlook
    • 4.3.1. Epidemiology and Patient Population
      • 4.3.1.1. Key Findings
      • 4.3.1.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 4.3.1.3. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
        • 4.3.1.3.1. United States
          • 4.3.1.3.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
          • 4.3.1.3.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2. EU5
          • 4.3.1.3.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
          • 4.3.1.3.2.2. UK
            • 4.3.1.3.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.3. France
            • 4.3.1.3.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.4. Germany
            • 4.3.1.3.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.5. Spain
            • 4.3.1.3.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.6. Italy
            • 4.3.1.3.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
            • 4.3.1.3.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
            • 4.3.1.3.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
            • 4.3.1.3.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.3. Japan
          • 4.3.1.3.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 4.3.2. Current Treatment Practices
      • 4.3.2.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
      • 4.3.2.2. Patient Journey
    • 4.3.3. Unmet Needs
    • 4.3.4. Organizations contributing toward IPF
    • 4.3.5. KOL's Views: Idiopathic Pulmonary Fibrosis
    • 4.3.6. Case Reports
      • 4.3.6.1. Idiopathic Pulmonary Fibrosis: As case Discussion in the US
      • 4.3.6.2. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A Case Report of Europe
      • 4.3.6.3. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis - A Japanese Case Report
    • 4.3.7. Marketed Drugs
      • 4.3.7.1. Esbriet (Pirfenidone): Inter Mune Inc.
        • 4.3.7.1.1. Product Description
        • 4.3.7.1.2. Regulatory Milestones
        • 4.3.7.1.3. Clinical Development
        • 4.3.7.1.4. Ongoing Current Pipeline Activity
        • 4.3.7.1.5. Safety and efficacy
        • 4.3.7.1.6. Product Profile
      • 4.3.7.2. OFEV (Nintedanib): BoehringerIngelheim Pharma GmbH and Co. KG
        • 4.3.7.2.1. Regulatory Milestones
        • 4.3.7.2.2. Clinical Development
        • 4.3.7.2.3. Ongoing Current Pipeline Activity
        • 4.3.7.2.4. Safety and efficacy
        • 4.3.7.2.5. Product Profile
    • 4.3.8. Emerging Drugs
      • 4.3.8.1. Tipelukast: MediciNova
        • 4.3.8.1.1. Product Description
        • 4.3.8.1.2. Other Development Activities
        • 4.3.8.1.3. Clinical Development
        • 4.3.8.1.4. Clinical Trials Information
        • 4.3.8.1.5. Safety and Efficacy
        • 4.3.8.1.6. Product Profile
      • 4.3.8.2. Pamrevlumab: FibroGen
        • 4.3.8.2.1. Product Description
        • 4.3.8.2.2. Other Development Activities
        • 4.3.8.2.3. Clinical Development
        • 4.3.8.2.4. Clinical Trials Information
        • 4.3.8.2.5. Safety and Efficacy
        • 4.3.8.2.6. Product Profile
      • 4.3.8.3. KD025: Kadmon Corporation, LLCs
        • 4.3.8.3.1. Product Description
        • 4.3.8.3.2. Other Development Activities
        • 4.3.8.3.3. Clinical Development
        • 4.3.8.3.4. Clinical Trials Information
        • 4.3.8.3.5. Safety and Efficacy
        • 4.3.8.3.6. Product Profile

(**to be continued in final report)

  • 4.4. PESTLE Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Market Dynamics and Trends
    • 4.6.1. Growth Drivers
    • 4.6.2. Restraints
    • 4.6.3. Challenges
    • 4.6.4. Key Trends
  • 4.7. Covid-19 Impact Assessment on Market Growth Trend
  • 4.8. Market Growth and Outlook
    • 4.8.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030
    • 4.8.2. Price Trend Analysis
  • 4.9. Competition Dashboard
    • 4.9.1. Market Concentration Rate
    • 4.9.2. Company Market Share Analysis (Value %), 2020
    • 4.9.3. Competitor Mapping

Chapter 5. Idiopathic Pulmonary Fibrosis Market Analysis, By Therapy

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 5.2.1. Esbriet (Pirfenidone)
    • 5.2.2. Ofev (Nintedanib)
    • 5.2.3. Tipelukast
    • 5.2.4. Pamrevlumab
    • 5.2.5. KD025
    • 5.2.6. PRM 151
    • 5.2.7. GKT831
    • 5.2.8. Others

Chapter 6. Idiopathic Pulmonary Fibrosis Market Analysis, By Region/Country

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 6.2.1. The U.S.
    • 6.2.2. The UK
    • 6.2.3. France
    • 6.2.4. Germany
    • 6.2.5. Spain
    • 6.2.6. Italy
    • 6.2.7. Japan

Chapter 7. The U.S. Idiopathic Pulmonary Fibrosis Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 7.2.1. By Therapy

Chapter 8. The UK Idiopathic Pulmonary Fibrosis Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 8.2.1. By Therapy

Chapter 9. France Idiopathic Pulmonary Fibrosis Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 9.2.1. By Therapy

Chapter 10. Germany Idiopathic Pulmonary Fibrosis Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 10.2.1. By Therapy

Chapter 11. Italy Idiopathic Pulmonary Fibrosis Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 11.2.1. By Therapy

Chapter 12. Spain Idiopathic Pulmonary Fibrosis Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 12.2.1. By Therapy

Chapter 13. Japan Idiopathic Pulmonary Fibrosis Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
    • 13.2.1. By Therapy

Chapter 14. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 14.1. Genentech, Inc.
  • 14.2. Boehringer Ingelheim Pharma GmbH and Co. Kg
  • 14.3. MediciNova
  • 14.4. FibroGen, Inc.
  • 14.5. Kadmon Corporation, LLC
  • 14.6. Promedior
  • 14.7. Genkyotex
  • 14.8. CelgeneCorporation
  • 14.9. ProMetic LifeSciences
  • 14.10. BioGen, Inc.
  • 14.11. Merck and Co.
  • 14.12. Novartis
  • 14.13. Other prominent players